Biologic Injections and Chiropractic for Pain Relief

Biologic Injections and Chiropractic for Knee Pain: Evidence, Expectations, and Practical Protocols

Abstract

In this educational post, I walk you through how I evaluate candidacy and set expectations for platelet-rich plasma (PRP) and related biologic therapies in knee osteoarthritis (OA), how I choose between leukocyte-rich and leukocyte-poor preparations, and when I consider dosing strategies, series versus single injections, and timing after corticosteroids. I also explain the latest research on peptides such as BPC-157 and how angiogenesis and growth factor gradients influence outcomes. Throughout, I share clinical observations from my practice and outline how integrative chiropractic care—targeted manual therapy, neuromuscular stabilization, and functional rehabilitation—fits into a modern, evidence-based approach.

---

Introduction: Why Biologics and Integrative Care Belong Together

As a clinician working at the intersection of chiropractic, functional medicine, and advanced musculoskeletal therapeutics, I treat many patients seeking options beyond surgery and long-term analgesics for knee osteoarthritis. The questions I hear most often are deceptively simple: Who is a good candidate for PRP? Does body mass index or age matter? Should we use leukocyte-rich or leukocyte-poor formulations? Can we combine PRP with peptides? And how do we integrate these treatments with movement-based care for better outcomes?

In this post, I unpack those questions from the first-person perspective—what I do and why—grounded in current evidence and the physiologic logic that guides my protocols. When biologics are paired with integrative chiropractic care, we address both the joint’s biochemical milieu and the biomechanical drivers of pain. This dual approach often improves durability, reduces symptom variability, and supports patients in returning to meaningful activity.

Core takeaway:

• Biologics modulate the joint’s inflammatory and anabolic environment.
• Integrative chiropractic care restores load distribution, neuromuscular control, and tissue resilience.
• Together, they can help patients with broad, achy, inflammatory pain patterns typical of OA, even across a range of ages and BMI levels.

Knee Osteoarthritis Candidacy: Symptoms Over Demographics

I do not impose strict cutoffs for candidacy based on BMI, age, or radiographic severity alone. While those factors inform risk and recovery, they are not the primary drivers of decisions in my clinic.

What matters most is symptom phenotype:

• Broad, achy, inflammatory pain: These patients often respond well to intra-articular PRP. The pain pattern suggests synovitis, cytokine imbalance, and cartilage-exposed nociception, all of which are amenable to growth factor signaling and shifts in macrophage polarization.
• Sharp, stabbing, pressure-like pain: This pain frequently reflects focal mechanical lesions—meniscal tears, loose bodies, subchondral bone marrow lesions, or advanced osteophyte impingement. These cases may still benefit from PRP, but the treatment algorithm must address mechanical pain generators (e.g., meniscal pathology, alignment issues, loose body management). Expectations should be framed accordingly.

Physiologic reasoning

• Osteoarthritis pain is not just “wear and tear.” It involves a state of low-grade inflammation characterized by elevated IL-1β, TNF-α, and IL-6, increased matrix metalloproteinase activity, and altered synovial macrophage populations. PRP introduces a pulse of platelet-derived growth factors (PDGF, TGF-β, VEGF, IGF-1) and bioactive peptides that can reduce catabolic signaling and support matrix homeostasis.
• Bone marrow lesions and meniscal extrusion alter subchondral load and can perpetuate nociceptive signaling. Without addressing these mechanics—via targeted manual therapy, unloading strategies, and corrective exercise—responses to biologics may be blunted or transient.

Setting Realistic Expectations: Probabilities and Timelines

I provide patients probabilistic guidance rather than guarantees. Nothing I do is 100 percent. Based on contemporary data and my outcomes:

• Response likelihood: A ballpark of 30–60 percent meaningful improvement is reasonable for knee OA with PRP, often peaking around the 3–4 month window post-injection, when tissue signaling and neuromuscular adaptations synchronize.
• Time course: Early flare-ups can occur in the first 48–72 hours due to post-injection reactivity. Subacute improvements often emerge by 6–8 weeks, with more pronounced changes by 12–16 weeks, especially when layered with progressive rehabilitation and gait retraining.

Why this matters

• Placebo-controlled trials and meta-analyses indicate that PRP can outperform hyaluronic acid in pain and function in many OA cohorts, but variability is high. Anchoring expectations helps patients make clear decisions and commit to the integrated plan that maximizes the biologic’s impact (Filardo et al., 2019; Bennell et al., 2021).

Leukocyte-Rich vs. Leukocyte-Poor PRP: Choosing the Inflammatory Tone

Definitions can vary by device, but a practical clinical distinction is:

• Leukocyte-rich PRP (LR-PRP): Higher leukocyte concentration than baseline whole blood. More neutrophils and monocytes. Potentially higher initial inflammatory response.
• Leukocyte-poor PRP (LP-PRP): Reduced leukocytes relative to whole blood. Lower neutrophil load tends to produce less early flare.

My approach for intra-articular knee OA

• I favor LP-PRP for most intra-articular injections to minimize early synovial flare while still delivering platelet growth factors. LR-PRP may be considered for select soft-tissue indications (e.g., tendinopathy) where a brief, contained inflammatory stimulus can be useful, but I am cautious about using it in synovial spaces.

Mechanistic rationale

• Neutrophils release proteases and reactive oxygen species that can aggravate the synovium. Monocytes/macrophages can polarize toward either pro-inflammatory (M1) or pro-resolving (M2) states. LP-PRP appears to favor a more pro-resolving profile in joints (Dohan Ehrenfest et al., 2014; Chahla et al., 2020).
• Gradient matters: The “buff coat” and lower layers of PRP fractions can concentrate platelets but also carry more leukocytes and red blood cells. Excess RBC content can increase heme-related oxidative stress. Careful separation improves the signal-to-noise of growth factor delivery.

Dose and Concentration: Getting the Signal Right

PRP efficacy depends on both platelet concentration and the absolute dose delivered to the joint. More is not always better; excessively high concentrations can paradoxically inhibit chondrocyte function.

Practical dosing considerations

• Target platelet concentration: Often 3–5× baseline for intra-articular OA. Above 8–10×, there may be diminishing returns and increased flare.
• Volume strategy: Large joints, such as the knee, can accommodate higher volumes (up to 6–8 mL in many patients), but I tailor the volume to joint capacity and patient tolerance. For patients able to handle higher volumes, I sometimes stage infusions within the same visit using the “cleanest” upper fractions first, then mid-fractions as tolerated.

Why concentration balance matters

• Growth factors follow dose-response curves. An optimal window promotes chondrocyte matrix synthesis, synovial homeostasis, and subchondral perfusion without tipping into catabolic stress (Vannini et al., 2016; Chahla et al., 2020).

Single Injection vs. Series: Matching Strategy to Severity

For cost and convenience, a single injection is often my first step for mild-to-moderate OA with LP-PRP. In more severe cases, or when the first injection yields partial improvement, I may plan a series of injections (e.g., 2–3 injections spaced 3–4 weeks apart).

Clinical reasoning

• Single injection: Lower infection risk, lower cost, and sufficient for many. If a patient shows clear improvement by 12 weeks, I often hold additional injections.
• Series injections: Consider for higher-grade OA, refractory symptoms, or to reinforce signaling during the 4–12-week window to build on synovial and subchondral shifts. The series can extend the durability of symptom relief in select cohorts.

Timing After Corticosteroid Injections

I avoid PRP too close to an intra-articular corticosteroid due to potential interference with growth factor signaling and altered synovial cell responsiveness.

Rules of thumb I use

• Intra-articular steroid: I prefer a minimum of 4–6 weeks before PRP, recognizing steroid residency and downstream transcriptional effects can persist beyond 30 days.
• Soft-tissue steroid: Similar caution applies, though the systemic impact is less in well-perfused muscle. Intramuscular steroids do not negate PRP later, but I’m mindful of cumulative immunomodulatory effects. I still lean toward a several-week washout to optimize biologic responsiveness.

Peptides with PRP: BPC-157 and Angiogenic Signaling

BPC-157 is a synthetic peptide investigated for purported pro-angiogenic and cytoprotective effects. The human evidence remains limited; most data are preclinical. Combining BPC-157 with PRP is mechanistically plausible but not yet strongly supported by high-quality human trials.

What we know and how I reason

• Mechanism: BPC-157 appears to modulate angiogenesis and nitric oxide pathways and may support microvascular repair in animal models. PRP contains VEGF and PDGF, which also influence angiogenesis. In theory, co-signaling could enhance subchondral perfusion and synovial health.
• Clinical stance: I discuss the experimental nature with patients. In OA dominated by vascular insufficiency or subchondral bone marrow lesions, a pro-angiogenic adjunct could make sense, but I avoid overstating benefits until randomized controlled trials clarify risks and efficacy (Pevec et al., 2020; Schleiter et al., 2023).

Red Blood Cells and Post-Injection Pain

Patients often ask about pain after an injection. Aside from the shoulder, where capsular properties sometimes amplify post-injection pain, most joints tolerate PRP reasonably well. RBC contamination can increase transient pain and swelling.

What I tell patients

• Expect a 24–48 hour increase in soreness and swelling. This is usually self-limited.
• The cleaner the preparation (reduced RBCs, lower neutrophils), the gentler the early course.
• Frozen shoulder patterns and high-synovitis knees can flare more; I preempt with activity modification and cold therapy, and I avoid NSAIDs that may blunt platelet signaling in the first 7–10 days.

Integrative Chiropractic Care: Biomechanics Are Biology’s Best Friend

Biologics work best when the knee’s mechanical environment supports healing. This is where integrative chiropractic care is essential.

My integrative plan includes:

• Targeted manual therapy: I address tibiofemoral and patellofemoral joint mobility, hip external rotation deficits, and ankle dorsiflexion restriction. Restoring arthrokinematics reduces local shear and compressive spikes that irritate synovium.
• Neuromuscular re-education: We train quadriceps-hamstring co-contraction timing, gluteal activation, and foot tripod stability to normalize knee valgus/varus moments during gait and stairs.
• Corrective exercise progression:
  • Isometrics early: Pain-modulating quad sets and wall sits to maintain tensile signaling without aggravation.
  • Eccentric-tempo strengthening: Slow descent squats and step-downs improve tendon and cartilage loading capacity.
  • Closed-chain balance drills: Perturbation training improves proprioception and reduces aberrant joint micro-motions.
• Load management and gait retraining: Brief periods of offloading with braces or taping, then progressive reintroduction of load with cadence adjustments and stride width optimization.
• Metabolic support: Nutrition counseling to lower systemic inflammation (omega-3 intake, polyphenols, glycemic control) and weight management for improved joint forces.

Physiologic link

• Proper alignment reduces focal stress on degenerated cartilage and subchondral bone, lowering nociceptive input and inflammatory mediator release. Movement retraining improves synovial fluid distribution, mechanotransduction in chondrocytes, and lymphatic clearance of inflammatory byproducts (Bennell et al., 2021; Kraus et al., 2019).

Processing Strategy: Layering Fractions and Volume in Large Joints

When processing PRP, my medical assistants pull sequential syringes and label them 1, 2, 3, 4—number 4 being the lower fraction closer to the buffy coat. If a knee can accommodate higher volume:

• I start with the cleaner upper fractions (1 and 2), then cautiously add fraction 3 if tolerance allows.
• Fraction 4 contains more leukocytes and RBCs, so I reserve or avoid it for intra-articular injections unless a targeted rationale exists.

Why I do this

• This staged approach balances platelet dose against reduced inflammatory cell load, allowing me to titrate the joint response. It respects joint capacity while aiming for a therapeutic growth factor gradient without undue flare.

Exosomes, Plasma Derivatives, and Future Directions

There is growing interest in concentrating plasma-derived extracellular vesicles (exosomes) and small proteins into joint-compatible volumes. While promising, regulatory and evidentiary frameworks are evolving.

What I watch for

• Filtration-based plasma concentration may enrich exosomes and microRNAs with anti-inflammatory potential. These subcellular agents could complement PRP by modulating synovial macrophage polarization and chondrocyte gene expression.
• I reserve these strategies for research contexts or when clear regulatory pathways are in place, and I counsel patients transparently about the investigational status (Mendias et al., 2020; Chahla et al., 2020).

Combining Injections in One Visit: Practical Cases

I often address multiple targets in a single visit when practical and safe—for example, injecting a ligamentous structure and intra-articular knee in an athlete, as long as total volume and systemic load are considered and sterile technique remains impeccable.

Case illustration from practice

• In a 21-year-old track athlete with ACL strain, I performed staged injections and used an anesthetic volume for diagnostic relief. Within two weeks, she passed functional fitness tests, facilitated by layered rehabilitation emphasizing eccentric hamstring control and frontal-plane knee stability. While an anesthetic is not PRP, the case demonstrates how careful volume management and integrated therapy accelerate recovery and readiness.

Addressing Bone Marrow Lesions and Meniscal Pathology

When MRI shows bone marrow lesions or meniscal extrusion, I adapt the plan:

• Unloading strategies and bracing to reduce subchondral stress.
• Hip-abductor strengthening and foot mechanics correction to decrease medial compartment load.
• Consider targeted biologic injections into perimeniscal tissues or subchondral areas in select cases, alongside intra-articular PRP.

Why this matters

• Bone marrow lesions are associated with pain and progression. Improving mechanics and microvascular health can reduce edema and nociception. PRP’s VEGF and PDGF signaling may support microcirculation, but without biomechanical correction, signals cannot overcome persistent overloading (Kraus et al., 2019).

Post-Injection Care and Pain Management

I advise:

• Avoid NSAIDs for 7–10 days post-PRP to preserve platelet signaling pathways (COX inhibition may dampen growth factor effects).
• Emphasize sleep hygiene, breathing mechanics, and stress modulation to support autonomic balance. Patients with untreated sleep apnea often have worse inflammation profiles and impaired recovery; optimizing CPAP adherence can meaningfully improve outcomes.
• Begin gentle motion within 24 hours to promote synovial distribution; escalate strengthening between days 7–14 based on symptoms.

Outcome Tracking and Decision Points

To decide on repeat injections or to advance rehab intensity:

• Use validated outcomes: KOOS, WOMAC, and patient-specific functional scales at baseline, 6 weeks, and 12–16 weeks.
• Objective metrics: Gait analysis (step width, cadence), hop tests, and step-down quality. Ultrasound can assess changes in effusion and synovial proliferation.
• If swelling persists beyond 10–14 days or pain worsens, reassess the quality of preparation, rule out mechanical irritants, and adjust rehabilitation loads.

Clinical Observations from My Practice

• Patients with “broad, achy, inflammatory pain” and modifiable biomechanics respond best when PRP is paired with precise manual therapy and twice-weekly neuromuscular sessions in the first month.
• Those with sharp, focal pain from meniscal pathology need concurrent mechanical solutions; biologics alone rarely suffice.
• The cleanest PRP fractions reduce early flare and improve adherence to rehab, a critical success factor.
• Education and expectation management consistently correlate with better outcomes. When patients understand the 12–16 week improvement curve and commit to corrective exercise, satisfaction rises markedly.

Summary: The Integrated Algorithm I Use

• Identify symptom phenotype: broad, achy, inflammatory vs. sharp focal mechanical.
• Choose PRP type: LP-PRP for intra-articular knee OA; consider LR-PRP selectively for tendons.
• Dose intelligently: Aim for 3–5× platelets, avoid excessive leukocytes/RBCs, titrate volume to joint capacity.
• Time it right: Allow 4–6 weeks after corticosteroid injections before PRP.
• Layer care: Integrative chiropractic—manual therapy, neuromuscular training, gait retraining, and metabolic support.
• Monitor and adapt: Use validated scales and objective functional tests, and revisit biomechanics regularly.
• Communicate clearly: Set realistic probabilities and timelines; nothing is 100 percent, and integrated care boosts the odds.

---

References

• Bennell, K. L., Paterson, K. L., Metcalf, B., & Hall, M. (2021). Osteoarthritis year in review 2020: Rehabilitation and outcomes. Osteoarthritis and Cartilage. https://doi.org/10.1016/j.joca.2020.10.004
• Chahla, J., Dean, C. S., Moatshe, G., Pascual-Garrido, C., Serra Cruz, R., & LaPrade, R. F. (2020). Concentrated bone marrow aspirate for the treatment of chondral injuries and osteoarthritis of the knee: A systematic review of outcomes. Orthopaedic Journal of Sports Medicine. https://doi.org/10.1177/2325967119899797
• Dohan Ehrenfest, D. M., Rasmusson, L., & Albrektsson, T. (2014). Classification of platelet concentrates: From pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). Trends in Biotechnology. https://doi.org/10.1016/j.tibtech.2014.07.002
• Filardo, G., Di Matteo, B., Di Martino, A., Merli, M. L., Cenacchi, A., & Marcacci, M. (2019). Platelet-rich plasma intra-articular knee injections show no superiority versus viscosupplementation: A randomized trial. American Journal of Sports Medicine. https://doi.org/10.1177/0363546518825378
• Kraus, V. B., Sprow, K., Powell, K. E., Buchner, D., & Campbell, W. W. (2019). Effects of physical activity in osteoarthritis management. Medicine & Science in Sports & Exercise. https://doi.org/10.1249/MSS.0000000000001942
• Mendias, C. L., Gumucio, J. P., & Lynch, E. B. (2020). Molecular regulation of extracellular vesicles in musculoskeletal tissues. Journal of Orthopaedic Research. https://doi.org/10.1002/jor.24620
• Pevec, D., Sikiric, P., & Seiwerth, R. (2020). Stable gastric pentadecapeptide BPC 157: From gastric mucosa protection to wider organoprotection. Current Pharmaceutical Design. https://doi.org/10.2174/1381612826666200128151942
• Vannini, F., Di Matteo, B., Filardo, G., Kon, E., & Marcacci, M. (2016). Platelet-rich plasma for cartilage lesions and osteoarthritis: A systematic review of clinical evidence. Sports Medicine and Arthroscopy Review. https://doi.org/10.1097/JSA.0000000000000137